1,646
Views
58
CrossRef citations to date
0
Altmetric
Editorials

Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone

Pages 11-17 | Published online: 20 Mar 2012
 

ABSTRACT

Most available postmenopausal hormone replacement therapies (HRT) offer similar efficacy, but differ with respect to the cardiovascular risks associated with their use. There is a wealth of evidence to suggest that, unlike oral estrogens, transdermal estradiol does not increase the risk of venous thromboembolism, probably due to its lack of effect on the coagulation cascade, including thrombin generation and resistance to activated protein C, and does not increase the risk of stroke. It is cardioprotective, significantly reducing the incidence of myocardial infarction compared with non-users; it significantly reduces the incidence of new-onset diabetes, a risk factor for myocardial infarction. Micronized progesterone has also been shown not to increase the risk of venous thromboembolism and further reduced the incidence of new-onset diabetes when combined with transdermal estrogen. Micronized progesterone has a neutral effect on the vasculature, including a neutral or beneficial effect on blood pressure. Therefore, experimental and clinical data indicate that transdermal estradiol and micronized progesterone could represent the optimal HRT, particularly in women at risk of adverse events.

ACKNOWLEDGEMENT

Assistance with writing this manuscript was provided by Clare Ryles, medical writer, and funded by Besins Healthcare.

Conflict of interest A. O. Mueck has been involved in trials and/or experimental research regarding hormone replacement therapy sponsored by Bayer Schering, Jenapharm, Dr. Kade/Besins, Wyeth, MSD and Novartis. He has received from those companies consultancy fees, lecture fees and financial support to conduct research on sexual steroids. He serves on the board of several societies and journals covering this issue. He is President of the German Menopause Society.

Source of funding The content of this article was based on a presentation given at a symposium, sponsored by Besins Healthcare, at the 2011 World Congress on Menopause of the International Menopause Society.

Log in via your institution

Log in to Taylor & Francis Online

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 277.00 Add to cart

* Local tax will be added as applicable
 

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.